RA Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

RA Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.3M	Buy	12,723,026 +5,918,954	+87%	+$26.4M	0.58%	33
2026 Q1	$25.5M	Buy	+6,804,072	New	+$23M	0.27%	52
2025 Q2	–	Sell	-4,666,667	Closed	-$7.14M	–	64
2025 Q1	$7.14M	Hold	4,666,667	–	–	0.12%	71
2024 Q4	$11.6M	Buy	+4,666,667	New	+$11.6M	0.15%	71
2023 Q4	–	Sell	-4,398,453	Closed	-$30.1M	–	63
2023 Q3	$30.1M	Hold	4,398,453	–	–	0.59%	44
2023 Q2	$45.6M	Hold	4,398,453	–	–	0.86%	34
2023 Q1	$35.6M	Hold	4,398,453	–	–	0.81%	38
2022 Q4	$69.3M	Hold	4,398,453	–	–	1.41%	24
2022 Q3	$69.2M	Hold	4,398,453	–	–	1.48%	21
2022 Q2	$61.4M	Buy	4,398,453 +2,580,645	+142%	+$36.2M	1.64%	17
2022 Q1	$31.3M	Buy	+1,817,808	New	+$24.8M	0.68%	45
2016 Q4	–	Sell	-1,547,152	Closed	-$39.6M	–	28
2016 Q3	$39.6M	Sell	1,547,152 -1,080,567	-41%	-$22.9M	4.09%	8
2016 Q2	$48.5M	Hold	2,627,719	–	–	6.72%	5
2016 Q1	$49.8M	Buy	2,627,719 +63,166	+2%	+$1.21M	6.36%	4
2015 Q4	$69.1M	Buy	+2,564,553	New	+$50M	6.84%	5

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RA Capital Management's ACRS Position: Q2 2026 in Review

RA Capital Management increased its Aclaris Therapeutics (ACRS) stake by 87% in Q2 2026, buying an estimated $26.4M and bringing the position to 12,723,026 shares worth $67.3M. The position accounts for 0.58% of the portfolio, ranked #33.

RA Capital Management first reported a position in ACRS in Q4 2015 and has held it in 15 quarters since. The position peaked at $69.3M in Q4 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

RA Capital Management held 12,723,026 shares of Aclaris Therapeutics worth $67.3M as of Q2 2026.
RA Capital Management bought 5,918,954 Aclaris Therapeutics shares in Q2 2026, an estimated $26.4M.
Aclaris Therapeutics made up 0.58% of RA Capital Management's portfolio in Q2 2026, its #33 holding.
RA Capital Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 15 quarters since.
RA Capital Management's Aclaris Therapeutics position peaked at $69.3M in Q4 2022.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.